Vivimed Labs CIRP update: CoC meetings in Aug-Sep 2026

What Vivimed Labs told the exchanges

Vivimed Labs Ltd (BSE: 532660; NSE: VIVIMEDLAB) has informed BSE about further meetings of its Committee of Creditors (CoC) under the Corporate Insolvency Resolution Process (CIRP). The disclosure places the next milestone on the calendar with a CoC meeting scheduled for September 10, 2026. The exchange update follows an earlier intimation that the company’s sixth CoC meeting was scheduled for August 18, 2026.

The company operates in the Pharmaceuticals and Drugs segment, and the continuing CIRP process is a key corporate event that investors typically track through periodic CoC updates filed with the exchanges.

The scheduled CoC meeting on September 10, 2026

The latest update references an upcoming CoC meeting as part of the CIRP framework. As per the information shared, the CoC meeting is scheduled for September 10, 2026. The exchange intimation is positioned as a procedural update to keep the market informed about the insolvency resolution timeline.

While the disclosure in the provided text does not list agenda items for the September 10 meeting, such meetings generally take forward discussions between financial creditors and the resolution professional on process milestones and decisions required under the Insolvency and Bankruptcy Code.

The sixth CoC meeting on August 18, 2026

Before the September meeting, Vivimed Labs had intimated BSE that its sixth Committee of Creditors meeting under CIRP would be held on August 18, 2026. The communication states that the meeting would be conducted through audio-visual means.

The exchange update is consistent with a series of CIRP-related filings that mark sequential CoC meetings as the insolvency process progresses.

CIRP background: NCLT order and the first CoC meeting

The information provided also notes that the CIRP was initiated following an NCLT order dated April 15, 2026, which placed the company under the Corporate Insolvency Resolution Process. In the timeline shared, the first meeting of the Committee of Creditors was convened on May 13, 2026.

These dates establish the formal start of the creditor-driven process and show that the company has since moved through multiple CoC meetings, including the sixth meeting scheduled for August 18, 2026.

Other corporate-event disclosures mentioned alongside CIRP

Alongside CIRP-related updates, the provided text references board meeting schedules connected to the company’s financial results process for FY 2025-26. One exchange note mentions that the board meeting to approve audited financial results for Q4 and the year ended March 31, 2026 had been rescheduled from May 28, 2026 to May 30, 2026, with the meeting to be held in Hyderabad.

The text also includes a separate update indicating that a board meeting was postponed from May 30, 2026, with a new date to be announced later. In addition, it mentions that the company informed BSE about a board meeting scheduled for July 17, 2026, to consider and approve quarter and year-end results (as of March 31, 2026). These items appear in the broader stream of disclosures, separate from the CoC meeting intimations.

Why CoC meeting intimations matter to investors

CoC meetings are central to the CIRP process because they serve as formal checkpoints where creditors review progress and consider steps required under the insolvency framework. For listed companies, exchange intimations help ensure that market participants receive time-stamped updates on key process events.

For shareholders and other stakeholders, such updates do not on their own indicate an outcome. They do, however, confirm the process is continuing and that further decisions will be routed through scheduled CoC meetings.

Key facts at a glance

Market-impact context: what the disclosures change and what they do not

The disclosed information is primarily procedural, confirming meeting dates under the CIRP structure. It adds clarity on the sequence of CoC meetings, including the August 18 sixth meeting and the subsequent meeting planned for September 10. This can be relevant for investors who track the progression of the insolvency process through formal milestones.

At the same time, the provided text does not include details such as voting outcomes, resolution plans, recovery estimates, or creditor decisions. As a result, the update should be read as a timeline marker rather than a statement about financial performance or a specific resolution outcome.

Conclusion

Vivimed Labs has continued to update the exchanges on milestones in its Corporate Insolvency Resolution Process, with the sixth CoC meeting scheduled for August 18, 2026 and another CoC meeting scheduled for September 10, 2026. The next updates are likely to come through further exchange filings tied to CoC proceedings and any subsequent corporate disclosures already referenced in the company’s board meeting communications.